4519.T
CHUGAI PHARMACEUTICAL CO.,LTD.
プライム · 医薬品 · 医薬品 · JP
JPY 6,878.00
+0.67%Sep 2, 2026, 09:17 UTC
Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.
Source:Aug 28, 2026, 09:39 UTC
Chugai Pharmaceutical submitted a manufacturing and marketing approval application to Japan's Ministry of Health, Labour and Welfare for its anti-IL-6 monoclonal antibody 'Vamikibart' for the indication of macular edema associated with non-infectious uveitis.
Source:Aug 18, 2026, 02:38 UTC
Chugai Pharmaceutical and GlaxoSmithKline signed an exclusive license agreement on August 18, 2026, granting GSK global rights to develop, manufacture, and commercialize the dengue antibody drug AID351, with Chugai eligible for royalties and a share of sublicensing revenue.
Source:Aug 5, 2026, 08:25 UTC
Chugai Pharmaceutical has applied to the Ministry of Health, Labour and Welfare for manufacturing and marketing approval of the therapeutic drug "satralizumab" for the prevention of relapse of MOG antibody-associated disease (MOGAD) as the intended indication. If approved, it would be the first insurance-covered therapeutic drug in Japan.
Source:Aug 4, 2026, 04:39 UTC
Chugai Pharmaceutical has signed a partnership agreement with the Japan Basketball Association (JBA) as a "Healthcare Innovation Partner".
Source: